Vaxcyte Key Executives
This section highlights Vaxcyte's key executives, including their titles and compensation details.
Find Contacts at Vaxcyte
(Showing 0 of )
Vaxcyte Earnings
This section highlights Vaxcyte's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-28 | N/A | N/A |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
$31.20
Stock Price
$4.02B
Market Cap
414
Employees
San Carlos, CA
Location
Financial Statements
Access annual & quarterly financial statements for Vaxcyte, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $75.00M | $9.20M | $1.80M | $1.41M |
| Gross Profit | $- | $-75.00M | $-9.20M | $-1.80M | $-1.41M |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $476.64M | $332.34M | $169.45M | $78.41M | $73.56M |
| General and Administrative Expenses | $92.90M | $60.70M | $39.81M | $25.26M | $16.02M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $92.90M | $60.70M | $39.81M | $25.26M | $16.02M |
| Other Expenses | $- | $- | $-1.93M | $-1.58M | $-2.48M |
| Operating Expenses | $569.55M | $468.04M | $207.33M | $102.08M | $87.10M |
| Cost and Expenses | $- | $468.04M | $207.33M | $102.08M | $87.10M |
| Interest Income | $109.99M | $62.91M | $8.36M | $344.00K | $244.00K |
| Interest Expense | $- | $- | $2.00K | $7.00K | $7.00K |
| Depreciation and Amortization | $- | $3.16M | $9.20M | $1.80M | $1.41M |
| EBITDA | $-569.55M | $-464.88M | $-214.29M | $-98.28M | $-87.81M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-569.55M | $-468.04M | $-232.26M | $-103.67M | $-89.58M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $105.62M | $65.78M | $8.77M | $3.59M | $364.00K |
| Income Before Tax | $-463.93M | $-402.27M | $-223.49M | $-100.08M | $-89.22M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $16.16M | $7.00K | $-1.40M |
| Net Income | $-463.93M | $-402.27M | $-239.64M | $-100.08M | $-87.82M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-3.80 | $-4.14 | $-3.69 | $-1.93 | $-2.97 |
| EPS Diluted | $-3.80 | $-4.14 | $-3.69 | $-1.93 | $-2.97 |
| Weighted Average Shares Outstanding | 122.00M | 97.16M | 64.88M | 51.92M | 29.55M |
| Weighted Average Shares Outstanding Diluted | 122.00M | 97.16M | 64.88M | 51.92M | 29.55M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $14.45M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $4.50M | $3.48M | $3.09M | $2.95M | $2.48M | $2.40M | $2.34M | $2.30M | $2.35M | $2.16M | $2.37M | $1.21M | $846.00K | $868.00K | $527.00K | $- | $- | $- | $- |
| Gross Profit | $- | $-4.50M | $-3.48M | $-3.09M | $11.50M | $-2.48M | $-2.40M | $-2.34M | $-2.30M | $-2.35M | $-2.16M | $-2.37M | $-1.21M | $-846.00K | $-868.00K | $-527.00K | $- | $- | $- | $- |
| Gross Profit Ratio | - | - | - | - | 79.59% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $133.61M | $116.94M | $131.51M | $94.59M | $104.15M | $97.42M | $72.69M | $58.08M | $51.63M | $47.68M | $38.47M | $31.68M | $23.07M | $20.43M | $17.65M | $17.26M | $14.66M | $16.41M | $18.18M | $24.32M |
| General and Administrative Expenses | $28.55M | $22.99M | $21.47M | $19.89M | $17.53M | $15.61M | $14.46M | $13.11M | $11.95M | $10.90M | $9.42M | $7.54M | $6.77M | $6.52M | $6.08M | $5.88M | $4.79M | $4.90M | $3.05M | $3.28M |
| Selling and Marketing Expenses | $- | $- | $-3.48M | $- | $-2.95M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $28.55M | $22.99M | $18.00M | $19.89M | $14.58M | $15.61M | $14.46M | $13.11M | $11.95M | $10.90M | $9.42M | $7.54M | $6.77M | $6.52M | $6.08M | $5.88M | $4.79M | $4.90M | $3.05M | $3.28M |
| Other Expenses | $- | $- | $-394.00K | $- | $75.65M | $- | $- | $-654.00K | $-925.00K | $-157.00K | $-690.00K | $-160.00K | $-908.00K | $-299.00K | $-378.00K | $- | $- | $- | $- | $- |
| Operating Expenses | $162.17M | $139.92M | $149.50M | $114.35M | $118.73M | $113.03M | $84.68M | $70.54M | $62.65M | $58.42M | $47.20M | $39.06M | $28.94M | $26.65M | $23.35M | $23.14M | $19.13M | $20.52M | $20.19M | $27.27M |
| Cost and Expenses | $162.17M | $139.92M | $152.98M | $114.35M | $121.68M | $113.03M | $84.68M | $70.54M | $62.65M | $58.42M | $47.20M | $39.06M | $28.94M | $26.65M | $23.35M | $23.14M | $19.13M | $20.52M | $20.19M | $27.27M |
| Interest Income | $36.46M | $28.06M | $23.81M | $21.67M | $17.57M | $18.50M | $16.45M | $10.39M | $6.63M | $1.19M | $399.00K | $134.00K | $99.00K | $90.00K | $93.00K | $61.00K | $32.00K | $33.00K | $44.00K | $135.00K |
| Interest Expense | $- | $- | $- | $- | $10.73M | $- | $- | $- | $6.63M | $1.19M | $2.00K | $134.00K | $- | $- | $7.00K | $- | $- | $- | $- | $7.00K |
| Depreciation and Amortization | $4.79M | $- | $3.48M | $3.09M | $2.95M | $2.48M | $2.40M | $2.34M | $2.30M | $2.35M | $2.16M | $2.37M | $1.21M | $846.00K | $868.00K | $527.00K | $332.00K | $334.00K | $355.00K | $384.00K |
| EBITDA | $-52.58M | $-139.92M | $-152.98M | $-113.47M | $-177.85M | $-90.18M | $-87.15M | $-70.48M | $-75.71M | $-55.56M | $-47.89M | $-36.62M | $-27.36M | $-25.77M | $-22.81M | $-22.62M | $-20.41M | $-20.72M | $-19.92M | $-26.75M |
| EBITDA Ratio | - | - | - | - | -1231.16% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-162.17M | $-139.92M | $-152.98M | $-114.47M | $-121.68M | $-113.03M | $-87.15M | $-71.19M | $-86.57M | $-58.58M | $-47.89M | $-39.22M | $-29.85M | $-26.95M | $-23.73M | $-23.14M | $-19.45M | $-21.31M | $-21.22M | $-27.60M |
| Operating Income Ratio | - | - | - | - | -842.28% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $25.09M | $36.80M | $24.28M | $19.45M | $15.88M | $20.36M | $18.81M | $10.73M | $8.52M | $660.00K | $-646.00K | $235.00K | $1.28M | $336.00K | $51.00K | $1.92M | $-1.28M | $290.00K | $904.00K | $454.00K |
| Income Before Tax | $-137.08M | $-103.12M | $-128.70M | $-95.02M | $-180.80M | $-92.66M | $-68.34M | $-60.46M | $-78.05M | $-57.92M | $-48.53M | $-38.99M | $-28.56M | $-26.61M | $-23.68M | $-21.22M | $-20.74M | $-21.02M | $-20.32M | $-27.14M |
| Income Before Tax Ratio | - | - | - | - | -1251.56% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $-19.33M | $14.58M | $-2.48M | $2.28M | $-12.10M | $15.40M | $-660.00K | $646.00K | $-235.00K | $- | $10.00K | $7.00K | $- | $-332.00K | $-334.00K | $- | $7.00K |
| Net Income | $-137.08M | $-103.12M | $-128.70M | $-95.02M | $-180.80M | $-92.66M | $-68.34M | $-48.36M | $-93.45M | $-57.26M | $-49.18M | $-38.75M | $-28.56M | $-26.61M | $-23.68M | $-21.22M | $-20.74M | $-21.02M | $-20.32M | $-27.14M |
| Net Income Ratio | - | - | - | - | -1251.56% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-1.12 | $-0.83 | $-1.10 | $-0.85 | $-1.76 | $-0.91 | $-0.70 | $-0.56 | $-1.18 | $-0.92 | $-0.81 | $-0.68 | $-0.54 | $-0.51 | $-0.46 | $-0.41 | $-0.41 | $-1.02 | $-1.72 | $-6.70 |
| EPS Diluted | $-1.12 | $-0.83 | $-1.10 | $-0.85 | $-1.76 | $-0.91 | $-0.70 | $-0.56 | $-1.18 | $-0.92 | $-0.81 | $-0.67 | $-0.54 | $-0.51 | $-0.46 | $-0.41 | $-0.41 | $-1.02 | $-1.72 | $-6.70 |
| Weighted Average Shares Outstanding | 122.85M | 123.69M | 117.26M | 111.69M | 102.53M | 101.67M | 98.06M | 86.21M | 79.01M | 61.99M | 60.82M | 57.33M | 52.81M | 52.19M | 51.48M | 51.17M | 50.96M | 20.67M | 11.80M | 4.05M |
| Weighted Average Shares Outstanding Diluted | 122.85M | 123.69M | 117.26M | 111.69M | 102.53M | 101.67M | 98.06M | 86.21M | 79.01M | 61.99M | 60.82M | 57.55M | 52.81M | 52.19M | 51.51M | 51.17M | 50.96M | 20.67M | 11.80M | 4.05M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $387.88M | $397.45M | $834.66M | $68.98M | $386.20M |
| Short Term Investments | $1.36B | $682.78M | $96.72M | $176.99M | $- |
| Cash and Short Term Investments | $1.75B | $1.08B | $931.38M | $245.97M | $386.20M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $-1.00M | $-1.20M | $-300.00K |
| Other Current Assets | $40.78M | $15.73M | $5.31M | $9.18M | $2.50M |
| Total Current Assets | $1.79B | $1.10B | $942.55M | $256.35M | $389.00M |
| Property Plant Equipment Net | $270.15M | $110.62M | $31.65M | $35.91M | $3.27M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $1.39B | $162.68M | $26.55M | $27.12M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $65.68M | $38.66M | $5.43M | $4.96M | $550.00K |
| Total Non-Current Assets | $1.72B | $311.96M | $63.62M | $67.99M | $3.82M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.51B | $1.41B | $1.01B | $324.34M | $392.83M |
| Account Payables | $48.45M | $14.59M | $9.79M | $6.76M | $29.79M |
| Short Term Debt | $5.89M | $7.11M | $11.82M | $10.55M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $85.84M | $123.64M | $18.91M | $11.41M | $17.08M |
| Total Current Liabilities | $140.18M | $145.34M | $40.52M | $28.72M | $46.86M |
| Long Term Debt | $65.22M | $22.11M | $12.03M | $11.51M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $100.00K | $- | $9.00K | $96.00K | $122.00K |
| Total Non-Current Liabilities | $65.32M | $22.11M | $12.04M | $11.60M | $122.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $205.50M | $167.45M | $52.56M | $40.32M | $46.98M |
| Preferred Stock | $- | $- | $- | $324.34M | $392.83M |
| Common Stock | $128.00K | $98.00K | $82.00K | $56.00K | $54.00K |
| Retained Earnings | $-1.39B | $-924.39M | $-522.13M | $-298.64M | $-198.56M |
| Accumulated Other Comprehensive Income Loss | $-3.87M | $179.00K | $-361.00K | $-241.00K | $-392.83M |
| Other Total Stockholders Equity | $4.70B | $2.16B | $1.48B | $582.84M | $151.53M |
| Total Stockholders Equity | $3.31B | $1.24B | $953.61M | $284.02M | $345.84M |
| Total Equity | $3.31B | $1.24B | $953.61M | $284.02M | $345.84M |
| Total Liabilities and Stockholders Equity | $3.51B | $1.41B | $1.01B | $324.34M | $392.83M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.51B | $1.41B | $1.01B | $324.34M | $392.83M |
| Total Investments | $2.75B | $845.45M | $123.27M | $204.10M | $- |
| Total Debt | $71.11M | $29.22M | $17.94M | $16.78M | $- |
| Net Debt | $-316.77M | $-368.23M | $-816.72M | $-52.20M | $-386.20M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $387.88M | $1.05B | $518.67M | $611.51M | $397.45M | $545.13M | $531.03M | $949.85M | $834.66M | $366.20M | $238.17M | $201.74M | $68.98M | $112.04M | $151.00M | $198.94M | $386.20M | $397.05M | $410.05M | $154.79M |
| Short Term Investments | $1.36B | $1.13B | $934.03M | $875.01M | $682.78M | $720.55M | $756.03M | $441.59M | $96.72M | $83.83M | $116.33M | $132.90M | $176.99M | $166.53M | $141.12M | $122.18M | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.75B | $2.18B | $1.45B | $1.49B | $1.08B | $1.27B | $1.29B | $949.85M | $931.38M | $366.20M | $354.50M | $334.64M | $245.97M | $278.58M | $292.12M | $321.12M | $386.20M | $397.05M | $410.05M | $154.79M |
| Net Receivables | $- | $17.87M | $17.88M | $- | $- | $1.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $-9.52M | $12.45M | $- | $23.13M | $-2.40M | $-129.12M | $-1.00M | $-4.68M | $-700.00K | $-100.00K | $-1.20M | $-5.70M | $-400.00K | $- | $- | $- | $- | $- |
| Other Current Assets | $40.78M | $15.53M | $10.90M | $30.55M | $21.89M | $29.75M | $23.25M | $18.64M | $5.31M | $6.83M | $8.53M | $7.48M | $9.18M | $18.67M | $9.02M | $7.19M | $2.50M | $2.99M | $2.01M | $3.80M |
| Total Current Assets | $1.79B | $2.21B | $1.48B | $1.52B | $1.10B | $1.30B | $1.31B | $840.67M | $942.55M | $369.76M | $363.73M | $342.22M | $256.35M | $302.95M | $301.53M | $324.71M | $389.00M | $400.83M | $413.06M | $158.59M |
| Property Plant Equipment Net | $332.62M | $249.93M | $152.75M | $157.31M | $110.62M | $27.76M | $34.43M | $34.86M | $31.65M | $32.83M | $34.73M | $36.26M | $35.91M | $6.93M | $6.31M | $6.02M | $3.27M | $2.54M | $2.75M | $3.34M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $1.39B | $1.09B | $400.35M | $413.25M | $163.78M | $168.56M | $153.73M | $127.81M | $26.55M | $3.98M | $6.86M | $17.70M | $27.12M | $39.73M | $48.84M | $49.75M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.20M | $3.37M | $52.69M | $3.67M | $37.56M | $4.29M | $4.35M | $4.81M | $5.43M | $5.50M | $6.30M | $6.54M | $4.96M | $4.45M | $1.38M | $1.86M | $550.00K | $442.00K | $438.00K | $603.00K |
| Total Non-Current Assets | $1.72B | $1.35B | $605.79M | $574.23M | $311.96M | $200.62M | $192.50M | $167.49M | $63.62M | $42.31M | $47.89M | $60.49M | $67.99M | $51.12M | $56.52M | $57.64M | $3.82M | $2.98M | $3.19M | $3.94M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.51B | $3.56B | $2.09B | $2.09B | $1.41B | $1.50B | $1.50B | $1.01B | $1.01B | $412.06M | $411.62M | $402.72M | $324.34M | $354.07M | $358.05M | $382.35M | $392.83M | $403.82M | $416.25M | $162.53M |
| Account Payables | $48.45M | $18.22M | $10.47M | $21.72M | $14.59M | $15.70M | $16.27M | $11.62M | $9.79M | $5.49M | $7.04M | $4.80M | $6.76M | $25.71M | $23.70M | $31.86M | $29.79M | $10.69M | $2.56M | $2.65M |
| Short Term Debt | $5.89M | $9.64M | $14.59M | $7.20M | $14.23M | $12.06M | $11.97M | $5.95M | $5.91M | $12.85M | $13.29M | $13.16M | $5.28M | $1.23M | $1.42M | $1.67M | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-65.92M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $85.84M | $95.93M | $57.80M | $58.19M | $116.53M | $57.80M | $31.98M | $35.19M | $24.82M | $20.97M | $10.14M | $9.29M | $16.68M | $20.52M | $15.59M | $21.49M | $17.08M | $28.93M | $30.34M | $21.87M |
| Total Current Liabilities | $140.18M | $123.79M | $82.85M | $87.10M | $145.34M | $85.56M | $60.22M | $52.75M | $40.52M | $39.31M | $30.47M | $27.25M | $28.72M | $47.46M | $40.70M | $55.02M | $46.86M | $39.61M | $32.89M | $24.52M |
| Long Term Debt | $65.22M | $18.32M | $18.29M | $20.22M | $22.11M | $7.78M | $9.22M | $10.64M | $12.03M | $13.36M | $14.56M | $15.83M | $11.51M | $553.00K | $225.00K | $295.00K | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $100.00K | $- | $- | $- | $- | $2.00K | $5.00K | $7.00K | $9.00K | $89.00K | $92.00K | $93.00K | $96.00K | $98.00K | $100.00K | $103.00K | $122.00K | $129.00K | $144.00K | $163.00K |
| Total Non-Current Liabilities | $65.32M | $18.32M | $18.29M | $20.22M | $22.11M | $7.78M | $9.23M | $10.64M | $12.04M | $13.45M | $14.65M | $15.93M | $11.60M | $651.00K | $325.00K | $398.00K | $122.00K | $129.00K | $144.00K | $163.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $205.50M | $142.11M | $101.14M | $107.32M | $167.45M | $93.34M | $69.44M | $63.39M | $52.56M | $52.75M | $45.12M | $43.17M | $40.32M | $48.11M | $41.03M | $55.41M | $46.98M | $39.74M | $33.04M | $24.68M |
| Preferred Stock | $- | $- | $3.13B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $354.07M | $358.05M | $382.35M | $- | $403.82M | $416.25M | $270.81M |
| Common Stock | $128.00K | $127.00K | $114.00K | $112.00K | $98.00K | $98.00K | $97.00K | $84.00K | $82.00K | $64.00K | $62.00K | $59.00K | $56.00K | $56.00K | $55.00K | $54.00K | $54.00K | $54.00K | $54.00K | $33.00K |
| Retained Earnings | $-1.39B | $-1.25B | $-1.15B | $-1.02B | $-924.39M | $-743.59M | $-650.93M | $-582.59M | $-522.13M | $-444.08M | $-386.16M | $-337.63M | $-298.64M | $-270.08M | $-243.46M | $-219.78M | $-198.56M | $-177.83M | $-156.81M | $-136.49M |
| Accumulated Other Comprehensive Income Loss | $-3.87M | $139.00K | $1.81M | $2.89M | $179.00K | $-2.29M | $-2.52M | $47.00K | $-361.00K | $-657.00K | $-904.00K | $-833.00K | $-241.00K | $-12.00K | $-8.00K | $-47.00K | $0 | $-3.83M | $-3.50M | $-3.37M |
| Other Total Stockholders Equity | $4.70B | $4.67B | $3.13B | $3.00B | $2.16B | $2.15B | $2.09B | $1.53B | $1.48B | $803.98M | $753.50M | $697.94M | $582.84M | $575.99M | $560.44M | $546.71M | $544.35M | $541.85M | $539.97M | $274.30M |
| Total Stockholders Equity | $3.31B | $3.42B | $1.99B | $1.98B | $1.24B | $1.40B | $1.43B | $944.77M | $953.61M | $359.31M | $366.50M | $359.54M | $284.02M | $305.96M | $317.02M | $326.94M | $345.84M | $364.07M | $383.21M | $137.85M |
| Total Equity | $3.31B | $3.42B | $1.99B | $1.98B | $1.24B | $1.40B | $1.43B | $944.77M | $953.61M | $359.31M | $366.50M | $359.54M | $284.02M | $305.96M | $317.02M | $326.94M | $345.84M | $364.07M | $383.21M | $137.85M |
| Total Liabilities and Stockholders Equity | $3.51B | $3.56B | $2.09B | $2.09B | $1.41B | $1.50B | $1.50B | $1.01B | $1.01B | $412.06M | $411.62M | $402.72M | $324.34M | $354.07M | $358.05M | $382.35M | $392.83M | $403.82M | $416.25M | $162.53M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.51B | $3.56B | $2.09B | $2.09B | $1.41B | $1.50B | $1.50B | $1.01B | $1.01B | $412.06M | $411.62M | $402.72M | $324.34M | $354.07M | $358.05M | $382.35M | $392.83M | $403.82M | $416.25M | $162.53M |
| Total Investments | $2.75B | $2.22B | $1.33B | $1.29B | $846.55M | $889.11M | $909.76M | $569.40M | $123.27M | $87.80M | $123.19M | $150.60M | $204.10M | $206.27M | $189.96M | $171.93M | $- | $- | $- | $- |
| Total Debt | $71.11M | $27.96M | $25.58M | $27.42M | $29.22M | $13.81M | $15.21M | $16.59M | $17.94M | $19.78M | $21.20M | $22.41M | $16.78M | $1.17M | $935.00K | $1.13M | $- | $- | $- | $- |
| Net Debt | $-316.77M | $-1.02B | $-493.09M | $-584.09M | $-368.23M | $-531.33M | $-515.83M | $-933.27M | $-816.72M | $-346.42M | $-216.97M | $-179.33M | $-52.20M | $-110.88M | $-150.06M | $-197.81M | $-386.20M | $-397.05M | $-410.05M | $-154.79M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-463.93M | $-402.27M | $-223.49M | $-100.08M | $-89.22M |
| Depreciation and Amortization | $15.85M | $10.17M | $9.20M | $3.46M | $1.41M |
| Deferred Income Tax | $- | $- | $- | $- | $301.00K |
| Stock Based Compensation | $84.82M | $48.76M | $23.65M | $10.73M | $5.43M |
| Change in Working Capital | $-54.90M | $81.32M | $12.74M | $-37.01M | $35.27M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $34.58M | $11.22M | $2.90M | $-12.47M | $26.10M |
| Other Working Capital | $-89.48M | $70.09M | $9.84M | $-24.54M | $9.17M |
| Other Non Cash Items | $-34.47M | $-34.77M | $7.30M | $1.50M | $179.00K |
| Net Cash Provided by Operating Activities | $-452.63M | $-296.79M | $-170.60M | $-121.39M | $-46.63M |
| Investments in Property Plant and Equipment | $-22.43M | $-67.88M | $-5.85M | $-6.55M | $-1.16M |
| Acquisitions Net | $- | $- | $7.00K | $26.00K | $50.00K |
| Purchases of Investments | $-3.09B | $-1.33B | $-102.75M | $-336.34M | $- |
| Sales Maturities of Investments | $1.20B | $624.46M | $183.17M | $130.56M | $- |
| Other Investing Activities | $-96.73M | $- | $80.43K | $-205.75K | $50 |
| Net Cash Used for Investing Activities | $-2.01B | $-773.31M | $74.58M | $-212.31M | $-1.10M |
| Debt Repayment | $- | $- | $- | $- | $-61.00K |
| Common Stock Issued | $2.44B | $636.04M | $856.48M | $13.90M | $264.01M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $12.85M | $3.77M | $5.07M | $3.90M | $110.92M |
| Net Cash Used Provided by Financing Activities | $2.45B | $639.81M | $861.55M | $17.80M | $374.87M |
| Effect of Forex Changes on Cash | $426.00K | $-6.69M | $137.00K | $-439.00K | $87.00K |
| Net Change in Cash | $-9.36M | $-436.97M | $765.67M | $-316.34M | $327.22M |
| Cash at End of Period | $389.19M | $398.55M | $835.53M | $69.86M | $386.20M |
| Cash at Beginning of Period | $398.55M | $835.53M | $69.86M | $386.20M | $58.98M |
| Operating Cash Flow | $-452.63M | $-296.79M | $-170.60M | $-121.39M | $-46.63M |
| Capital Expenditure | $-22.43M | $-67.88M | $-5.85M | $-6.55M | $-1.16M |
| Free Cash Flow | $-475.05M | $-364.67M | $-176.44M | $-127.95M | $-47.78M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-137.08M | $-103.12M | $-128.70M | $-95.02M | $-180.80M | $-92.66M | $-68.34M | $-60.46M | $-78.05M | $-57.92M | $-48.53M | $-38.99M | $-28.56M | $-26.61M | $-23.68M | $-21.22M | $-20.74M | $-21.02M | $-20.32M | $-27.14M |
| Depreciation and Amortization | $4.79M | $4.49M | $3.48M | $3.09M | $2.95M | $2.48M | $2.40M | $2.34M | $2.30M | $2.35M | $2.17M | $2.37M | $1.21M | $856.00K | $868.00K | $527.00K | $332.00K | $334.00K | $355.00K | $384.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-12.77M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $24.37M | $21.27M | $21.56M | $17.63M | $13.35M | $13.22M | $12.54M | $9.65M | $7.01M | $6.65M | $5.89M | $4.10M | $3.16M | $2.94M | $2.77M | $1.86M | $1.94M | $1.84M | $1.29M | $372.00K |
| Change in Working Capital | $-2.48M | $29.22M | $-7.79M | $-73.83M | $38.06M | $33.99M | $2.50M | $6.77M | $-3.30M | $10.61M | $1.04M | $4.39M | $-27.45M | $-6.05M | $-8.97M | $5.47M | $7.70M | $5.78M | $9.22M | $12.57M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $723.00K | $- | $- | $-723.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-10.59M | $- | $- | $14.09M |
| Accounts Payables | $31.31M | $8.31M | $-10.71M | $5.67M | $6.48M | $694.00K | $2.26M | $1.79M | $3.47M | $-1.35M | $2.71M | $-1.93M | $-18.07M | $1.50M | $1.92M | $2.19M | $18.77M | $8.13M | $-76.00K | $-723.00K |
| Other Working Capital | $-33.79M | $20.91M | $2.92M | $-7.97M | $31.59M | $33.29M | $233.00K | $4.98M | $-6.77M | $11.96M | $-1.67M | $6.33M | $-9.38M | $-7.55M | $-10.89M | $3.29M | $-1.21M | $-2.35M | $9.30M | $-67.00K |
| Other Non Cash Items | $-991.00K | $-12.56M | $-9.93M | $7.15M | $10.40M | $-14.57M | $-11.84M | $-5.99M | $6.82M | $-238.00K | $301.00K | $422.00K | $561.00K | $461.00K | $330.00K | $151.00K | $2.00K | $16.00K | $283.00K | $179.00K |
| Net Cash Provided by Operating Activities | $-111.40M | $-60.71M | $-121.39M | $-159.12M | $-128.81M | $-57.55M | $-62.74M | $-47.69M | $-65.22M | $-38.55M | $-39.13M | $-27.70M | $-51.09M | $-28.41M | $-28.68M | $-13.21M | $-10.77M | $-13.05M | $-9.17M | $-13.63M |
| Investments in Property Plant and Equipment | $-30.03M | $-38.08M | $-45.37M | $-12.07M | $-57.07M | $-7.34M | $2.14M | $-5.61M | $-1.15M | $-843.00K | $-938.00K | $-2.92M | $-1.38M | $-1.72M | $-2.21M | $-1.25M | $-722.00K | $-29.00K | $-55.00K | $-349.00K |
| Acquisitions Net | $- | $- | $- | $- | $-43.14K | $-29.62K | $335.70K | $442.49K | $34.80K | $-35.55K | $-27.10K | $7.00K | $26.00K | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-815.22M | $-1.23B | $-350.65M | $-687.70M | $-203.61M | $-209.67M | $-432.83M | $-483.78M | $-71.28M | $-17.59M | $-6.90M | $-6.97M | $-41.06M | $-66.75M | $-56.39M | $-172.15M | $- | $- | $- | $- |
| Sales Maturities of Investments | $288.07M | $354.20M | $309.22M | $248.70M | $246.75M | $239.29M | $97.13M | $41.29M | $36.48M | $53.14M | $34.00M | $59.55M | $42.50M | $50.00M | $38.06M | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $6.39M | $-6.39M | $43.14K | $29.62K | $-335.70K | $-442.49K | $-34.80K | $35.55K | $27.10K | $7.00K | $26.00K | $-16.75M | $38.06M | $-172.15M | $- | $50.00K | $- | $- |
| Net Cash Used for Investing Activities | $-557.17M | $-917.02M | $-80.41M | $-451.07M | $-13.93M | $22.28M | $-333.56M | $-448.10M | $-35.95M | $34.71M | $26.16M | $49.67M | $82.00K | $-18.47M | $-20.53M | $-173.39M | $-722.00K | $21.00K | $-55.00K | $-349.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $-60.00K |
| Common Stock Issued | $8.00K | $1.51B | $106.53M | $816.48M | $-23.00K | $49.00M | $545.28M | $41.79M | $653.62M | $43.12M | $49.00M | $110.74M | $6.79M | $7.11M | $956.00K | $487.00K | $635.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $5.53M | $- | $- | $5.58M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $374.00K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-313.00K | $- | $- | $- |
| Other Financing Activities | $4.90M | $2.40M | $3.83M | $1.72M | $2.73M | $-450.00K | $1.69M | $-225.00K | $3.02M | $896.00K | $874.00K | $282.00K | $1.97M | $491.00K | $956.00K | $487.00K | $555.00K | $36.00K | $264.48M | $109.86M |
| Net Cash Used Provided by Financing Activities | $4.91M | $1.52B | $110.37M | $818.20M | $2.73M | $48.55M | $546.97M | $41.56M | $656.63M | $44.02M | $49.88M | $111.02M | $8.75M | $7.60M | $956.00K | $487.00K | $555.00K | $36.00K | $264.48M | $109.80M |
| Effect of Forex Changes on Cash | $1.35M | $-5.58M | $-1.41M | $6.06M | $-7.68M | $1.05M | $-78.00K | $23.00K | $796.00K | $53.00K | $-485.00K | $-227.00K | $-802.00K | $333.00K | $311.00K | $-281.00K | $87.00K | $- | $- | $- |
| Net Change in Cash | $-662.31M | $532.84M | $-92.84M | $214.06M | $-147.68M | $14.33M | $150.58M | $-454.21M | $556.26M | $40.23M | $36.43M | $132.76M | $-43.06M | $-38.95M | $-47.94M | $-186.39M | $-10.85M | $-13.00M | $255.25M | $95.81M |
| Cash at End of Period | $389.19M | $1.05B | $518.67M | $612.62M | $397.45M | $546.24M | $531.90M | $381.32M | $835.53M | $279.27M | $239.04M | $202.61M | $69.86M | $112.92M | $151.87M | $199.81M | $386.20M | $397.05M | $410.05M | $154.79M |
| Cash at Beginning of Period | $1.05B | $518.67M | $611.51M | $398.55M | $545.13M | $531.90M | $381.32M | $835.53M | $279.27M | $239.04M | $202.61M | $69.86M | $112.92M | $151.87M | $199.81M | $386.20M | $397.05M | $410.05M | $154.79M | $58.98M |
| Operating Cash Flow | $-111.40M | $-60.71M | $-121.39M | $-159.12M | $-128.81M | $-57.55M | $-62.74M | $-47.69M | $-65.22M | $-38.55M | $-39.13M | $-27.70M | $-51.09M | $-28.41M | $-28.68M | $-13.21M | $-10.77M | $-13.05M | $-9.17M | $-13.63M |
| Capital Expenditure | $-30.03M | $-38.08M | $-45.37M | $-12.07M | $-57.07M | $-7.34M | $2.14M | $-5.61M | $-1.15M | $-843.00K | $-938.00K | $-2.92M | $-1.38M | $-1.72M | $-2.21M | $-1.25M | $-722.00K | $-29.00K | $-55.00K | $-349.00K |
| Free Cash Flow | $-141.43M | $-98.79M | $-166.77M | $-171.20M | $-185.88M | $-64.89M | $-60.60M | $-53.30M | $-66.37M | $-39.39M | $-40.06M | $-30.62M | $-52.48M | $-30.13M | $-30.89M | $-14.45M | $-11.49M | $-13.08M | $-9.23M | $-13.98M |
Vaxcyte Dividends
Explore Vaxcyte's dividend history, including dividend yield, payout ratio, and historical payments.
Vaxcyte News
Read the latest news about Vaxcyte, including recent articles, headlines, and updates.
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants.
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formulation for Advancement to Potential Infant Phase 3 Program, Pending Topline VAX-31 Infant Phase 2 Study Readout -- -- Company Announces VAX-XL, Third-Generation PCV Candidate Designed to Further Expand Spectrum of Coverage -- -- Company to Host Webcast/Conference Call Today at 8:00 a.m. ET / 5:00 a.m.
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 --
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later --
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines.
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five --
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 --
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 --
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PCVX.